 The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16 over the last twenty-one trading days, and it is up a solid 91 over the last twelve-month period. The rally in ALKS stock over the recent months has been propelled by the. 